Literature DB >> 30015973

Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors.

Shuang Lai1, Jun-Ning Chen2, Han-Wei Huang3, Xiang-Yu Zhang2, Hai-Lun Jiang2, Wei Li4, Peng-Liang Wang3, Jian Wang2, Fu-Nan Liu3.   

Abstract

Vascular endothelial growth factor receptor 2 (VEGFR2) and c‑Met are tyrosine kinases, which are involved in the tumorigenesis of various types of cancer. Previous studies have demonstrated that the elevated activation of c‑Met is associated with the drug resistance of VEGFR2 inhibitors. Therefore, dual c‑Met and VEGFR2 kinase inhibitors are expected to overcome VEGFR2 inhibitor resistance and subsequently lead to a superior therapeutic outcome to regular VEGFR2 inhibitors. In the present study, it was found that chrysoeriol, which can be extracted from several natural plants, was a potential dual c‑Met and VEGFR2 kinase inhibitor. The results of docking experiments revealed that chrysoeriol was able to efficiently bind in the active site cavity of c‑Met and VEGFR2. The results of enzymatic assays showed relatively high binding affinities of chrysoeriol to c‑Met (Kd=12 µM) and VEGFR2 (Kd=11 µM). The structure activity relationships (SARs) of chrysoeriol and its analogs were investigated using pharmacological and molecular docking experiments. To the best of our best knowledge, the present study is the first to report a natural product with both c‑Met and VEGFR2 inhibitory profiles, and provides insights into future dual c‑Met and VEGFR2 kinase inhibitor development.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30015973     DOI: 10.3892/or.2018.6542

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

Review 1.  Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016-Present).

Authors:  Qian Zhang; Pengwu Zheng; Wufu Zhu
Journal:  Molecules       Date:  2020-06-08       Impact factor: 4.411

Review 2.  Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.

Authors:  Yun Liu; Yang Li; Yuxi Wang; Congcong Lin; Dan Zhang; Juncheng Chen; Liang Ouyang; Fengbo Wu; Jifa Zhang; Lei Chen
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.